GE Healthcare is releasing two new new molecular imaging systems, the Discovery MI, a PET/CT scanner and Discovery NM/CT 670 CZT, a SPECT/CT system.
The Discovery MI is a PET/CT that as some of its features offers a large field of view for improved brain studies, the ability to detect faster decaying tracers than are currently used in clinical practice, enabling new research and compatibility with future medical tracers, and the greatest sensitivity in the business.
GE touts the Discovery NM/CT 670 CZT as the world’s first general purpose SPECT/CT imaging system with a cadmium zinc telluride (CZT) detector that converts gamma rays into electronic signals without using crystals or photomultiplier tubes. The technology allows for fast acquisition times and improved contrast and resolution to be able to detect small lesions. Previous CZT devices were made for use on specific organs, but the Discover NM/CT N670 CZT allows for scanning of any organ and even to perform full body exams.
Some details from GE’s announcement:
Discovery MI is the industry’s only PET/CT system that brings together the sensitivity of digital detection, with the most innovative reconstruction technology available: the combination of Time-of-Flight (TOF) and Q.Clear. The result is outstanding resolution to improve the detection of small lesions.
Discovery MI’s new LightBurst Digital Detector represents the next-generation for GE Healthcare’s vision for a digital future for PET. With this new detector, the system delivers up to two times improvement in volumetric resolution enabling small lesion detectability and has the highest NEMA sensitivity of any TOF/PET system in the industry. This system also features the latest diagnostic CT innovations with 100 percent better spatial resolution, with no increase in image noise with ASiR-VTM. And Smart Metal Artifact Reduction (MAR) virtually eliminates streaks and shadows from metal artifacts, saving valuable time previously spent correcting images, increasing the number of successful scans for patients.
Discovery NM/CT 670 CZT was engineered to deliver improvements in lesion detection, image quality and patient comfort and combined with advanced quantitative applications provided through Xeleris 4.0, it can help clinicians better diagnose and monitor diseases earlier. T
This system is intended to help improve the clinicians’ confidence and patient experience. The combined capabilities will allow clinicians to detect smaller lesions and quantify them more accurately due to the increased spatial and contrast resolution. This may have a significant role in assessing and monitoring responses to therapies. Having the ability to complete multiple scans in a single visit and reduce the injected dose or the scan time by 50 percent will improve patient experience. Optimizing the duration of the exams or the injected dose represents not only an improvement for the patient experience, but also could provide economic and clinical benefits.
Via: GE Healthcare…